The ClearNote Health team is grateful for the opportunity to help our patients live longer and healthier lives. We wish you a wonderful Thanksgiving filled with the warmth and happiness of the season. ??? ? We invite you to learn more about our mission and technology for early detection of high-mortality cancers by visiting us at: https://lnkd.in/eVE68cER #pancreaticcancer #pancreaticcancerawareness
ClearNote Health
生物技术研究
San Diego，California 3,243 位关注者
Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives.
关于我们
ClearNote Health – Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives. We focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics. We apply our proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases. Headquartered in the U.S, the company’s CLIA and CAP-accredited laboratory is located in San Diego, Calif., with additional presence in the San Francisco Bay Area and internationally. #biotechnology #epigenomics #oncology #cancerresearch #cancer
- 网站
-
https://www.clearnotehealth.com
ClearNote Health的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2016
地点
ClearNote Health员工
动态
-
Thank you to our colleague Margaret Freitag for sharing her very moving story about #pancreaticcancer on this World Pancreatic Cancer Day. #WPCD
? A Story About Pancreatic Cancer by Margaret Freitag We've all read in the news and in the scientific literature that the number of pancreatic cancer cases is increasing even though it's not clear what might be behind that. Among my friends and family, I can count seven people who have been affected by pancreatic cancer - sadly only one survives. Some of them had risk factors like Ashkenazi Jewish heritage, or new onset diabetes. In the case of my friends and family, those risk factors were only recognized in hindsight, and unfortunately all were diagnosed in advanced stages. I know what it's like to survive cancer, albeit not pancreatic. I was diagnosed with a rare cancer with an aggressive histology. I know the angst of waiting for the pathology to come back, for the staging to be confirmed; guessing my chances of making it out to other side. Fortunately, I was diagnosed at an early stage. I powered through surgery, chemotherapy and radiation over the course of nine months. I am grateful to celebrate my five-year survivor anniversary this year. My wishes during pancreatic cancer awareness month are that: ? More patients with pancreatic cancer can have the kind of chance that I had; an earlier diagnosis that allows for an increased chance of survival. ? More patients with risk factors for pancreatic cancer like family history, genetic predisposition and early onset diabetes become aware of these risks and the means for early diagnosis. That’s why I’m grateful to ClearNote Health and the dedicated #pancreaticcancer community in their pursuit of the early diagnosis and successful treatment of pancreatic cancer. #pancreaticcancerday ??
-
ClearNote Health is attending ISPOR—The Professional Society for Health Economics and Outcomes Research, Nov 17-20, 2024, in Barcelona. ? ClearNote Health’s?Senior Health Economics Consultant,?Adrian Vilalta, PhD, will present findings from a clinico-economic analysis of ClearNote Health’s Avantect Pancreatic Test in a poster entitled “Cell-Free DNA Epigenomic-based Test is Predicted to Be Cost Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer” (abstract #141003). ? If you are attending the event make sure not to miss his presentation to learn more about how?using the Avantect Pancreatic Cancer Test can be cost effective to manage individuals newly diagnosed with diabetes. #pancreaticcancer
-
-
We at ClearNote Health depend on our dedicated team members to provide patients at the highest risk of #pancreaticcancer with exceptional service and care. We want to highlight the contributions of Hong Nguyen and Roger Malta for their high level of commitment and passion for our mission. Hong Nguyen? ? Hong has gone above and beyond her role to support Quality Assurance documentation to enable flawless inspections of our workflows and processes.?? ? She has been instrumental in setting up the laboratory quality management system and guiding the team through important submission processes for CLIA, CAP, NY and FDA.?? ? Hong always takes the time to coach her peers across different functional groups to ensure that quality is maintained, exceeded, and consistent across all regulatory functions at ClearNote Health. Roger Malta? ? Roger has made important contributions to the development of new biomarker discovery methods. He is our lab soldier, very passionate and dedicated to advancing diagnostics for improved patient care. He is very quiet and unassuming but always ready to go the extra mile.??? ? He is in the lab first thing in the morning and ensures patient samples get processed with high quality. He demonstrates a high level of attention to details and technical competence while executing difficult R&D projects. ?? Thank you from all of us, Hong and Roger! Learn more ClearNote Health’s story and cutting-edge approach to early high-mortality cancer?detection at https://lnkd.in/eVE68cER
-
-
The ClearNote Health team will be at CGA IGC – Hereditary Gastrointestinal Cancer Annual Meeting, Nov 14-16, in Philadelphia.?? ? Meet us at booth #6 and learn how ClearNote’s proprietary epigenomic platform and cell-free DNA-based assays measure dynamic biological changes in cells to provide an early signal of a developing cancer.?? ? ?? Reach out to Laura Miles or Anna Bergamaschi to schedule a meeting in advance!?Contact us at [email protected]. #cellfreeDNA #epigenomics #cancer
-
-
?? Are you aware of the link between diabetes and cancer risk?? Dr. Steve Edelman (Taking Control Of Your Diabetes (TCOYD)) and Dr. David Diamond (ONCOLOGY PHYSICIANS OF FLORIDA, P.A) discuss the often-unknown link between diabetes and the risk of cancer. ?? They examine in detail the bi-directional nature of #type2diabetes and #pancreaticcancer. While just over 1% of patients will be diagnosed with pancreatic cancer, nearly 80% or more of all pancreatic cancer patients have a diabetes diagnosis offering an early sign that can lead to early intervention using a simple blood test. ????? Follow this link for the podcast:?https://lnkd.in/dn6-cB4x ? Explore ClearNote Health’s story and learn more about Avantect, our cutting-edge testing solution for the early detection of pancreatic cancer in high-risk patients: https://lnkd.in/djYeHasM
-
-
Accelerate your oncology drug development with non-invasive liquid biopsy.
Accelerate Your Oncology Research and Discovery
-
?? Did you know a new diagnosis of type 2 diabetes drastically increases the risk for pancreatic cancer? Learn more about the connection between diabetes and #pancreaticcancer in this short article written by the team at Taking Control Of Your Diabetes (TCOYD) Diabetes. Dr. Steve Edelman, nationally recognized expert in diabetes, discusses the often-unknown connection between a new diagnosis of #type2diabetes and an enhanced risk of pancreatic cancer in the first 36 months post diabetes diagnosis. While just over 1% of patients will be diagnosed with pancreatic cancer, nearly 80% or more of all pancreatic cancer patients have a diabetes diagnosis offering an early sign that can lead to early intervention.? ? ?? Follow this link for the full article:?https://lnkd.in/d4WhnAZR ?? Learn more about the Avantect Pancreatic Cancer Test and ClearNote Health’s story at: https://www.avantect.com/
-
-
?? ClearNote Health will be attending the American Association for Cancer Research Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation, Nov 12 –16 in San Diego.? ? Our Vice President, Translational Research and Head of Biopharma Development, Gulfem D. Guler, will be presenting a poster, titled:? ? Cancer-induced epigenomic changes in circulating immune cells enable breast, colorectal and lung cancer detection. ?? Poster Session A ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?? ??? Thursday, Nov 14, 5:15 - 7:15 p.m.? ? Traditional drug development processes are challenged by limited tissue availability and lack of tools that can capture tumor evolution and biology that is driven by non-genetic mechanisms. ClearNote Health addresses these challenges with its Virtuoso Epigenomics Platform, a groundbreaking whole genome sequencing and 5hmC enrichment solution designed to revolutionize translational research by revealing active disease biology to empower drug discovery and development. ? ? ?? Learn more at https://lnkd.in/d7aGzQAV or contact us at [email protected]. #epigenomics #drugdiscovery #liquidbiopsy
-
-
?? Did you know a new diagnosis of type 2 diabetes drastically increases the risk for pancreatic cancer? Learn more about the connection between diabetes and #pancreaticcancer in this short article written by the team at Taking Control Of Your Diabetes (TCOYD) Diabetes. Dr. Steve Edelman, nationally recognized expert in diabetes, discusses the often-unknown connection between a new diagnosis of #type2diabetes and an enhanced risk of pancreatic cancer in the first 36 months post diabetes diagnosis. While just over 1% of patients will be diagnosed with pancreatic cancer, nearly 80% or more of all pancreatic cancer patients have a diabetes diagnosis offering an early sign that can lead to early intervention.? ? ?? Follow this link for the full article:?https://lnkd.in/d4WhnAZR ?? Learn more about the Avantect Pancreatic Cancer Test and ClearNote Health’s story at: https://www.avantect.com/
-